Cash flow Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
190.02 USD | +0.99% | -1.05% | -19.62% |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 252M | 364M | 391M | 486M | 475M | |||||
Depreciation & Amortization - CF | 109M | 123M | 141M | 157M | 177M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 89.54M | 112M | 125M | 147M | 137M | |||||
Depreciation & Amortization, Total | 198M | 235M | 266M | 304M | 314M | |||||
Amortization of Deferred Charges, Total - (CF) | - | - | - | - | - | |||||
(Gain) Loss From Sale Of Asset | - | - | -25.03M | -123M | 961K | |||||
Asset Writedown & Restructuring Costs | - | - | - | - | 41.91M | |||||
(Income) Loss On Equity Investments - (CF) | -20.71M | -101M | 30.42M | 26.78M | -97.83M | |||||
Stock-Based Compensation (CF) | 57.27M | 56.34M | 71.47M | 73.62M | 72.05M | |||||
Provision and Write-off of Bad Debts | - | - | - | 6.71M | 18.22M | |||||
Net Cash From Discontinued Operations | - | - | - | - | - | |||||
Other Operating Activities, Total | -11.92M | 18.14M | -15.53M | -1.6M | -37.79M | |||||
Change In Accounts Receivable | -8.32M | -85.63M | -26.63M | -151M | -33.43M | |||||
Change In Inventories | -21.4M | -18.38M | -25.16M | -78.52M | -62.3M | |||||
Change In Accounts Payable | 29.78M | 748K | 44.9M | -2.65M | -20.43M | |||||
Change in Unearned Revenues | -14.52M | 37.6M | 3.52M | 88.12M | -37.31M | |||||
Change In Income Taxes | - | - | - | - | - | |||||
Change in Other Net Operating Assets | 20.64M | 39.38M | 46.31M | -8.92M | 51.09M | |||||
Cash from Operations | 481M | 547M | 761M | 620M | 684M | |||||
Capital Expenditure | -141M | -167M | -229M | -325M | -319M | |||||
Cash Acquisitions | -516M | -419M | -1.29B | -283M | -195M | |||||
Divestitures | - | - | 123M | 163M | - | |||||
Investment in Marketable and Equity Securities, Total | -21.4M | -15.29M | -39.02M | -154M | -47.55M | |||||
Other Investing Activities, Total | -3.89M | -1.06M | 264K | -9.35M | -2.29M | |||||
Cash from Investing | -682M | -602M | -1.44B | -608M | -563M | |||||
Long-Term Debt Issued, Total | 3.36B | 2.23B | 6.95B | 2.95B | 776M | |||||
Total Debt Issued | 3.36B | 2.23B | 6.95B | 2.95B | 776M | |||||
Long-Term Debt Repaid, Total | -3.12B | -2.2B | -6.24B | -2.93B | -852M | |||||
Total Debt Repaid | -3.12B | -2.2B | -6.24B | -2.93B | -852M | |||||
Issuance of Common Stock | 34.55M | 46.59M | 45.65M | 25.11M | 25.6M | |||||
Repurchase of Common Stock | -18.09M | -23.98M | -40.71M | -38.65M | -24.16M | |||||
Other Financing Activities, Total | -18.4M | -5.95M | -40.58M | -48.65M | -11.64M | |||||
Cash from Financing | 232M | 47.25M | 673M | -42.4M | -85.52M | |||||
Foreign Exchange Rate Adjustments | 11.36M | 794K | 17.73M | 25.58M | 8.04M | |||||
Net Change in Cash | 42.73M | -6.93M | 13.2M | -5.1M | 43.27M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 67.81M | 72.46M | 70.78M | 101M | 132M | |||||
Cash Income Tax Paid (Refund) | 54.06M | 60.06M | 75.44M | 75.91M | 90.37M | |||||
Levered Free Cash Flow | 350M | 270M | 631M | 299M | 219M | |||||
Unlevered Free Cash Flow | 388M | 324M | 677M | 336M | 304M | |||||
Change In Net Working Capital | -43.61M | 75.73M | -172M | 128M | 174M | |||||
Net Debt Issued / Repaid | 234M | 30.59M | 708M | 19.79M | -75.32M |